Carbapenems (CARBs) are the primary treatment for infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae strains. Production of a serine carbapenemase, KPC, is increasing alarmingly in the United States and is probably contributing to CARB resistance rates. We describe the clinical and molecular characteristics of four infections caused by KPC-3 K. pneumoniae strains.
Cookie SettingseScholarship uses cookies to ensure you have the best experience on our website. You can manage which cookies you want us to use.Our Privacy Statement includes more details on the cookies we use and how we protect your privacy.